The collaboration with University Medical Centre Groningen (UMCG) will add further data on the utility of KidneyIntelX™ in Chronic Kidney Disease (CKD) in identifying patients with fast-progressing kidney disease who are most likely to benefit from pharmaceutical intervention with new therapies (e.g. SGLT-2inhibitors). We continue to believe that KidneyIntelX™ is poised to address a vast unmet need in CKD, and deliver substantial healthcare savings. We look forward to the results of the ongoing ....
07 May 2019
Collaboration with UMCG: further validation for KidneyIntelX™
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Collaboration with UMCG: further validation for KidneyIntelX™
Renalytix Plc (RENX:LON) | 30.0 0 0.0% | Mkt Cap: 37.9m
- Published:
07 May 2019 -
Author:
Jens Lindqvist -
Pages:
3
The collaboration with University Medical Centre Groningen (UMCG) will add further data on the utility of KidneyIntelX™ in Chronic Kidney Disease (CKD) in identifying patients with fast-progressing kidney disease who are most likely to benefit from pharmaceutical intervention with new therapies (e.g. SGLT-2inhibitors). We continue to believe that KidneyIntelX™ is poised to address a vast unmet need in CKD, and deliver substantial healthcare savings. We look forward to the results of the ongoing ....